Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

ALKS

Alkermes plc

Mar 06 • 01:25PM ET

28.28

-0.07 -0.24 %

Healthcare • Drug Manufacturers - Specialty & Generic • Ireland • NASD

Peers: AMGN LLY MRK JNJ PFE BIIB BMY VRTX GILD REGN

| Held by: IJR VTI AVUV VB IWM XBI FBT VBK VXF SPSM

Scroll to Statements

Index	RUT	P/E	19.74	EPS (ttm)	1.43	Insider Own	2.02%	Shs Outstand	165.61M	Perf Week	-6.04%
Market Cap	4.71B	Forward P/E	31.49	EPS next Y	0.90	Insider Trans	-3.74%	Shs Float	163.28M	Perf Month	-17.13%
Enterprise Value	3.46B	PEG	61.74	EPS next Q	-0.43	Inst Own	108.55%	Short Float	10.91%	Perf Quarter	-4.23%
Income	241.66M	P/S	3.19	EPS this Y	-121.84%	Inst Trans	3.65%	Short Ratio	9.08	Perf Half Y	-2.21%
Sales	1.48B	P/B	2.57	EPS next Y	387.65%	ROA	10.54%	Short Interest	17.82M	Perf YTD	1.08%
Book/sh	10.99	P/C	3.57	EPS next 5Y	0.51%	ROE	14.72%	52W High	36.32 -22.12%	Perf Year	-18.38%
Cash/sh	7.92	P/FCF	9.81	EPS past 3/5Y	- -	ROIC	12.84%	52W Low	25.17 12.39%	Perf 3Y	11.77%
Dividend Est.	-	EV/EBITDA	12.32	Sales past 3/5Y	9.90% 7.28%	Gross Margin	86.31%	Volatility	3.40% 3.39%	Perf 5Y	57.80%
Dividend TTM	-	EV/Sales	2.35	EPS Y/Y TTM	-34.36%	Oper. Margin	17.21%	ATR (14)	1.17	Perf 10Y	-6.62%
Dividend Ex-Date	-	Quick Ratio	3.19	Sales Y/Y TTM	-5.25%	Profit Margin	16.37%	RSI (14)	30.05	Recom	1.41
Dividend Gr. 3/5Y	- -	Current Ratio	3.55	EPS Q/Q	-66.92%	SMA20	-11.27%	Beta	0.56	Target Price	43.65
Payout	0.00%	Debt/Eq	0.04	Sales Q/Q	-10.57%	SMA50	-10.06%	Rel Volume	0.69	Prev Close	28.35
Employees	2050	LT Debt/Eq	0.03	Earnings	Feb 25 BMO	SMA200	-5.24%	Avg Volume	1.96M	Price	28.28
IPO	Jul 16, 1991	Option/Short	Yes / Yes	EPS/Sales Surpr.	-29.30% 1.48%	Trades		Volume	839,339	Change	-0.24%

Date	Action	Analyst	Rating Change	Price Target Change
Feb-24-26	Initiated	Wolfe Research	Outperform	$45
Nov-11-25	Initiated	Truist	Buy	$50
Sep-26-25	Upgrade	RBC Capital Mkts	Sector Perform → Outperform	$44
Sep-03-25	Initiated	Wells Fargo	Overweight	$44
Jul-15-25	Initiated	Goldman	Buy	$43
Jun-17-25	Upgrade	UBS	Neutral → Buy	$42
May-28-25	Initiated	Needham	Buy	$45
Mar-13-25	Initiated	RBC Capital Mkts	Sector Perform	$40
Mar-04-25	Upgrade	UBS	Sell → Neutral	$21 → $38
Feb-11-25	Initiated	Deutsche Bank	Buy	$40
Nov-05-24	Upgrade	Stifel	Hold → Buy	$25 → $36
Jun-17-24	Initiated	TD Cowen	Buy	$34
Mar-19-24	Initiated	Robert W. Baird	Outperform	$37
Feb-20-24	Downgrade	UBS	Neutral → Sell	$25
Nov-20-23	Resumed	JP Morgan	Neutral	$33
Oct-24-23	Upgrade	Evercore ISI	In-line → Outperform
Oct-17-23	Initiated	UBS	Neutral	$31
Nov-03-22	Upgrade	Piper Sandler	Neutral → Overweight	$26 → $30
Oct-14-22	Upgrade	BofA Securities	Underperform → Neutral	$27 → $25
Aug-16-22	Initiated	Piper Sandler	Neutral	$26

Show Previous Ratings

Today 03:00AM	Biopharmas recent string of CEO splits (Pharma Voice)
Mar-02-26 10:02PM	Alkermes Pivots Deeper Into Sleep Medicine After Avadel Deal, Details Orexin Phase 3 at TD Cowen (MarketBeat)
Feb-26-26 11:40AM	Alkermes Down Despite Q4 Earnings Beat, Announces Leadership Change (Zacks)
Feb-25-26 02:03PM	Alkermes PLC (ALKS) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ... (GuruFocus.com) -7.04%
12:32PM	Alkermes plc Q4 2025 Earnings Call Summary (Moby)
12:30PM	Loading…
12:30PM	Alkermes (ALKS) Reports Q4 Earnings: What Key Metrics Have to Say (Zacks)
12:15PM	Alkermes (ALKS) Q4 Earnings and Revenues Top Estimates (Zacks)
11:02AM	Alkermes Q4 Earnings Call Highlights (MarketBeat)
07:43AM	Alkermes: Q4 Earnings Snapshot (Associated Press Finance)
07:00AM	Alkermes plc Reports Financial Results for the Fourth Quarter and Year Ended Dec. 31, 2025 and Provides Financial Expectations for 2026 (Business Wire)
06:55AM	Alkermes plc Announces CEO Succession Plan (Business Wire)
06:54AM	Alkermes Richard Pops to step down after three-decade run as CEO (BioPharma Dive)
Feb-24-26 04:00PM	Alkermes to Present at the TD Cowen 46th Annual Health Care Conference (Business Wire)
09:15AM	Wall Street's Insights Into Key Metrics Ahead of Alkermes (ALKS) Q4 Earnings (Zacks)
08:00AM	Here Are Tuesdays Top Wall Street Analyst Research Calls: Blackstone, Blue Owl Capital, Booking Holdings, Cheniere Energy, Comcast, Dominos Pizza, KeyCorp, Qualcomm, and More (24/7 Wall St.)
11:59AM	Loading…
Feb-19-26 11:59AM	BHC Stock Down on Q4 Earnings Miss, Salix Drives Revenue Growth (Zacks)
07:34AM	ImmunityBio Wins EU Nod for Bladder Cancer Combo Therapy, Stock Up (Zacks)
Feb-18-26 11:31AM	FDA Accepts BMY's NDA for Iberdomide Combo in Multiple Myeloma (Zacks)
11:24AM	Krystal Biotech Q4 Earnings Beat Estimates, Revenues Miss Mark (Zacks)
09:41AM	EU Approves Novo Nordisk's Higher-Dose Wegovy for Obesity Patients (Zacks)
09:40AM	Is Alkermes (ALKS) Stock Outpacing Its Medical Peers This Year? (Zacks)
09:32AM	Cytokinetics Wins EU Approval for Cardiovascular Drug Myqorzo (Zacks)
Feb-17-26 12:10PM	Will Alkermes (ALKS) Beat Estimates Again in Its Next Earnings Report? (Zacks)
Feb-13-26 01:11PM	Waters Q4 Earnings Surpass Estimates, Revenues Increase Y/Y (Zacks)
12:55PM	SNY Stock Falls After Board Suddenly Makes Leadership Change (Zacks)
11:53AM	VRTX's Q4 Earnings Miss Mark, Revenues Beat on Higher Product Sales (Zacks)
10:33AM	Agios Pharmaceuticals Incurs Narrower-Than-Expected Q4 Loss (Zacks)
10:23AM	Ultragenyx Q4 Loss Wider Than Expected, Revenues Increase Y/Y (Zacks)
10:20AM	NVS Reports Positive Late-Stage Data on Kidney Disease Drug Vanrafia (Zacks)
10:19AM	ALNY Q4 Earnings Beat, Sales Miss Despite Y/Y Growth, Stock Down (Zacks)
10:04AM	Loading…
10:04AM	CRSP Posts Wider-Than-Expected Loss in Q4, Sales Miss Estimates (Zacks)
Feb-12-26 10:38AM	MDGL Strengthens MASH Franchise With New Genetic Approaches (Zacks)
10:30AM	Zoetis Stock Gains After Q4 Earnings & Revenues Beat Estimates (Zacks)
07:30AM	Alkermes plc Completes Acquisition of Avadel Pharmaceuticals plc, Accelerating Entry Into Sleep Medicine Market (Business Wire)
Feb-11-26 04:00PM	Alkermes to Report Fourth Quarter and Year-End Financial Results on Feb. 25, 2026 (Business Wire)
12:57PM	Pharma companies left out of Trump's drug-pricing deals look for way in (Reuters)
10:45AM	MRNA Down Nearly 10% as FDA Refuses to Review Influenza Vaccine BLA (Zacks)
Feb-10-26 10:43AM	SNY's Rare Disease Drug Wins FDA Breakthrough and Japan Orphan Status (Zacks)
10:38AM	INCY Q4 Earnings Miss Estimates, Revenues Beat on Higher Product Sales (Zacks)
Feb-09-26 11:42AM	IMVT Posts Narrower-Than-Expected Q3 Loss, Pipeline in Focus (Zacks)
Feb-06-26 01:58PM	Mettler-Toledo Q4 Earnings Top Estimates, Sales Rise Y/Y (Zacks)
11:45AM	GSK Gets EU Approval for Expanded Use of Nucala in COPD (Zacks)
11:31AM	KOD Stock Up 24% in 3 Months: Here's What You Need to Know (Zacks)
Feb-05-26 11:42AM	Verastem Stock Rises Nearly 8% on Strong Q4 & 2025 Preliminary Results (Zacks)
10:49AM	Bristol-Myers Stock Up as Q4 Earnings and Revenues Beat Estimates (Zacks)
Feb-04-26 10:11AM	FDA Rejects AZN's Saphnelo SubQ Formulation, Priority Tag to Datroway (Zacks)
09:16AM	NVO Q4 Earnings & Sales Beat Estimates, Stock Down on Poor 2026 View (Zacks)
Feb-03-26 11:59AM	Sanofi's Venglustat Meets Primary Endpoints in Gaucher Disease Study (Zacks)
11:36AM	MRK Q4 Earnings & Sales Beat Estimates, Stock Down on Weak '26 View (Zacks)
10:43AM	NVO's CagriSema Outshines Semaglutide in Phase III Diabetes Study (Zacks)
09:27AM	Here's Why Gilead Sciences Stock Surged 21% in a Month (Zacks)
07:52AM	Acadia Expects Negative CHMP Opinion for Rett Syndrome Drug in EU (Zacks)
Feb-02-26 11:03AM	Ultragenyx Pharmaceutical Resubmits UX111 BLA for Sanfilippo Syndrome (Zacks)
09:40AM	Is Alkermes (ALKS) Outperforming Other Medical Stocks This Year? (Zacks)
Jan-30-26 10:24AM	FDA Accepts SMMT's Application Seeking Approval for NSCLC Drug (Zacks)
10:11AM	KYMR Initiates Dosing in Mid-Stage Asthma Study of Lead Candidate (Zacks)
Jan-29-26 11:52AM	HALO Rises Nearly 4% on Strong 2025 Preliminary Data and 2026 Guidance (Zacks)
11:23AM	TEVA's Q4 Earnings Beat, Branded Drugs Drive Revenue Growth (Zacks)
08:53AM	Biogen's Autoimmune Disease Candidate Gets FDA's Breakthrough Status (Zacks)
08:34AM	Are Options Traders Betting on a Big Move in Alkermes Stock? (Zacks)
Jan-28-26 09:45AM	NTLA Stock Up More Than 6% as FDA Lifts ATTRv-PN Study Clinical Hold (Zacks)
Jan-27-26 02:07PM	BHC's Late-Stage Liver Cirrhosis Studies Fail, Stock Down (Zacks)
12:15PM	Corvus Pharmaceuticals Stock Rallies 209% in a Month: Here's Why (Zacks)
10:53AM	RVMD Stock Tumbles as MRK Reportedly Withdraws Buyout Offer (Zacks)
10:50AM	SRPT Stock Up 8% on Positive Long-Term Data From Elevidys Study in DMD (Zacks)
Jan-23-26 11:13AM	CORT Rises as Relacorilant Meets OS Endpoint in Ovarian Cancer Study (Zacks)
Jan-22-26 02:17PM	Alkermes Stock Earns Technical Rating Upgrade (Investor's Business Daily)
11:39AM	MRNA & MRK's Personalized Cancer Therapy Delivers Strong 5-Year Data (Zacks)
03:09AM	Jim Cramer on Alkermes: "I Think It's a Hold, Maybe a Weak One" (Insider Monkey)
Jan-21-26 10:46AM	ImmunityBio Stock Soars on FDA Talks for Anktiva sBLA Resubmission (Zacks) +6.61%
10:31AM	FDA Grants Breakthrough Therapy Tag to LLY's Ovarian Cancer Candidate (Zacks)
10:12AM	NVO Expands Aspect Tie-Up to Advance Curative Diabetes Cell Therapies (Zacks)
Jan-19-26 10:36AM	ImmunityBio Shares Surge on Updated Durable Lymphoma Study Results (Zacks)
09:17AM	CytomX Stock Rises 31% in a Month: Here's What You Should Know (Zacks)
Jan-16-26 08:28PM	Lightning Round: Medline is 'unbelievable', it's a buy, says Jim Cramer (CNBC TV)
11:08AM	Mirum Stock Rises 7% in a Week: Here's What You Should Know (Zacks)
09:06AM	Erasca Stock Surges 42% in a Week: Here's What You Should Know (Zacks)
Jan-15-26 11:16AM	Apellis Stock Crashes 23% in a Week: Here's What You Should Know (Zacks)
09:40AM	Are Medical Stocks Lagging Alkermes (ALKS) This Year? (Zacks)
Jan-14-26 12:10PM	Will Alkermes (ALKS) Beat Estimates Again in Its Next Earnings Report? (Zacks) +5.04%
10:18AM	PCRX, LG Chem Partner to Expand Exparel Reach Across the Asia-Pacific (Zacks)
03:33AM	Best Value Stocks to Buy for Jan.14 (Zacks)
Jan-13-26 06:23PM	Alkermes Touts $10B Sleep Market as ALKS 2680 Heads to Phase 3, Avidel Deal Nears Close (MarketBeat)
Jan-07-26 11:45AM	FDA Grants Breakthrough Therapy Designation to ALKS' Narcolepsy Drug (Zacks)
Jan-06-26 07:00AM	Alixorexton Granted Breakthrough Therapy Designation by U.S. FDA for the Treatment of Narcolepsy Type 1 (Business Wire)
Dec-30-25 04:00PM	Alkermes to Present at the 44th Annual J.P. Morgan Healthcare Conference (Business Wire)
Dec-22-25 06:50AM	Why Analysts are Rating Alkermes (ALKS) a Buy (Insider Monkey)
Dec-08-25 09:40AM	Are Investors Undervaluing Alkermes (ALKS) Right Now? (Zacks)
Nov-27-25 11:30AM	Why Is Alkermes (ALKS) Down 5.5% Since Last Earnings Report? (Zacks)
Nov-25-25 04:00PM	Alkermes to Participate in Two Upcoming Investor Conferences (Business Wire)
Nov-20-25 12:33PM	AGIO Stock Hits 52-Week Low on Mixed Sickle Cell Disease Study Results (Zacks)
09:14AM	ALKS Raises Its Offer to Buy Avadel In Response to Lundbeck's Proposal (Zacks)
Nov-19-25 04:22PM	Alkermes Ups Its Avadel Bid To $2.37 Billion In A Buyout Battle With Lundbeck (Investor's Business Daily)
01:44PM	Alkermes prevails over Lundbeck in Avadel bidding war (Pharmaceutical Technology)
10:59AM	Insmed Stock Rise on EU Nod for Lung Disease Drug, Brinsupri (Zacks)
09:12AM	Looking for Earnings Beat? Buy These 5 Top-Ranked Stocks (Zacks)
08:53AM	BAYRY Obtains Approval for Hormone Free VMS Treatment Lynkuet in the EU (Zacks)
06:00AM	Alkermes plc Announces Increased Offer to Acquire Avadel Pharmaceuticals plc (PR Newswire)
05:33AM	Alkermes escalates bidding war; US biotech risks falling behind China (BioPharma Dive)
12:25AM	TD Cowen Asserts Buy Rating as Alkermes plc (ALKS) Delivers Topline Results for Narcolepsy Treatment (Insider Monkey)

Alkermes Plc is a global biopharmaceutical company, which engages in the business of developing, manufacturing, and commercializing medicines designed to address unmet medical needs of patients in major therapeutic areas such as alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline of product candidates in development for neurological disorders and cancer. Its proprietary products include ARISTADA, ARISTADA INITIO, LYBALVI, and VIVITROL. The company was founded in 1987 and is headquartered in Dublin, Ireland.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Parisi Samuel Joseph	VP, Finance (Interim PAO)	Mar 02 '26	Sale	29.29	6,890	201,808	7,717	Mar 04 08:19 PM
Nichols Christian Todd	SVP, Chief Commercial Officer	Mar 02 '26	Sale	30.00	6,000	180,000	109,769	Mar 04 08:18 PM
Hopkinson Craig C.	EVP R&D, Chief Medical Officer	Mar 02 '26	Option Exercise	19.34	5,000	96,700	98,389	Mar 04 08:16 PM
Hopkinson Craig C.	EVP R&D, Chief Medical Officer	Mar 02 '26	Sale	29.72	9,000	267,485	89,389	Mar 04 08:16 PM
Gaffin David Joseph	EVP, CLO, Alkermes, Inc.	Mar 03 '26	Sale	29.76	2,034	60,532	235,626	Mar 04 08:15 PM
Gaffin David Joseph	EVP, CLO, Alkermes, Inc.	Mar 02 '26	Sale	29.29	2,034	59,576	237,660	Mar 04 08:15 PM
Gaffin David Joseph	Officer	Mar 03 '26	Proposed Sale	29.76	2,034	60,532		Mar 03 05:12 PM
Nichols Christian Todd	Officer	Mar 02 '26	Proposed Sale	30.00	6,000	180,000		Mar 02 05:15 PM
Gaffin David Joseph	Officer	Mar 02 '26	Proposed Sale	29.29	2,034	59,576		Mar 02 05:07 PM
Hopkinson Craig C.	Officer	Mar 02 '26	Proposed Sale	29.72	9,000	267,485		Mar 02 04:36 PM
Hopkinson Craig C.	EVP R&D, Chief Medical Officer	Feb 02 '26	Option Exercise	19.34	5,000	96,700	66,740	Feb 02 08:52 PM
Hopkinson Craig C.	EVP R&D, Chief Medical Officer	Feb 02 '26	Sale	33.93	9,000	305,384	57,740	Feb 02 08:52 PM
Cooke Shane	Director	Feb 02 '26	Option Exercise	31.64	61,200	1,936,368	164,944	Feb 02 08:48 PM
Cooke Shane	Director	Feb 02 '26	Sale	34.57	61,200	2,115,673	103,744	Feb 02 08:48 PM
Cooke Shane	Officer	Feb 02 '26	Proposed Sale	34.57	61,200	2,115,674		Feb 02 04:05 PM
Hopkinson Craig C.	Officer	Feb 02 '26	Proposed Sale	33.93	9,000	305,384		Feb 02 04:02 PM
Hopkinson Craig C.	Officer	Jan 08 '26	Proposed Sale	30.00	5,000	150,005		Jan 08 07:38 PM
Hopkinson Craig C.	EVP R&D, Chief Medical Officer	Jan 08 '26	Option Exercise	19.34	5,000	96,700	66,740	Jan 08 05:23 PM
Hopkinson Craig C.	EVP R&D, Chief Medical Officer	Jan 08 '26	Sale	30.00	5,000	150,005	61,740	Jan 08 05:23 PM
Hopkinson Craig C.	EVP R&D, Chief Medical Officer	Jan 02 '26	Sale	28.00	4,000	112,000	61,740	Jan 02 04:39 PM
Hopkinson Craig C.	Officer	Jan 02 '26	Proposed Sale	28.00	4,000	112,000		Jan 02 04:36 PM
Hopkinson Craig C.	EVP R&D, Chief Medical Officer	Dec 03 '25	Option Exercise	19.34	3,748	72,486	69,488	Dec 05 04:21 PM
Hopkinson Craig C.	EVP R&D, Chief Medical Officer	Dec 03 '25	Sale	30.00	3,748	112,447	65,740	Dec 05 04:21 PM
Hopkinson Craig C.	Officer	Dec 03 '25	Proposed Sale	30.00	3,748	112,447		Dec 03 04:32 PM
Hopkinson Craig C.	EVP R&D, Chief Medical Officer	Dec 01 '25	Sale	29.30	4,000	117,200	65,740	Dec 01 05:41 PM
Hopkinson Craig C.	Officer	Dec 01 '25	Proposed Sale	29.30	4,000	117,200		Dec 01 04:45 PM
Hopkinson Craig C.	EVP R&D, Chief Medical Officer	Nov 03 '25	Option Exercise	19.34	5,000	96,700	78,740	Nov 03 04:37 PM
Hopkinson Craig C.	EVP R&D, Chief Medical Officer	Nov 03 '25	Sale	30.38	9,000	273,442	69,740	Nov 03 04:37 PM
Hopkinson Craig C.	Officer	Nov 03 '25	Proposed Sale	30.38	9,000	273,442		Nov 03 04:35 PM
Hopkinson Craig C.	EVP R&D, Chief Medical Officer	Oct 15 '25	Option Exercise	19.34	5,000	96,700	82,740	Oct 15 06:47 PM
Hopkinson Craig C.	EVP R&D, Chief Medical Officer	Oct 15 '25	Sale	31.53	9,000	283,776	73,740	Oct 15 06:47 PM
Hopkinson Craig C.	Officer	Oct 15 '25	Proposed Sale	31.53	9,000	283,777		Oct 15 04:07 PM
Nichols Christian Todd	SVP, Chief Commercial Officer	Jun 09 '25	Sale	31.95	3,333	106,489	89,542	Jun 10 04:39 PM
Nichols Christian Todd	SVP, Chief Commercial Officer	Jun 10 '25	Sale	31.09	3,334	103,654	86,208	Jun 10 04:39 PM
Nichols Christian Todd	Officer	Jun 10 '25	Proposed Sale	31.09	3,334	103,654		Jun 10 04:29 PM
Nichols Christian Todd	Officer	Jun 09 '25	Proposed Sale	31.95	3,333	106,489		Jun 09 04:08 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ALKS

Alkermes plc

Upgrade your FINVIZ experience